Adipokines as immunometabolic bridges: Linking obesity susceptibility, periodontal disease, hypertension, and systemic health
By Anne O. Rice, BS, RDH, CDP, FAAOSH
Originally at rdhmag.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Periodontal disease is now recognized as both a driver and a biomarker of systemic inflammation via adipokines, giving dental practices a new revenue stream and a stronger clinical rationale for integrated obesity-hypertension screening.
Key points
- Adipokines (leptin, adiponectin, resistin) are detectable in saliva and correlate with pocket depth and bleeding on probing, offering a potential chair-side adjunct for risk stratification.
- Patients with both periodontitis and elevated BMI show a 1.6-fold higher prevalence of undiagnosed hypertension, increasing medical-legal exposure for dentists who ignore blood-pressure trends.
- DSO and large-group practices can position periodontal therapy as a billable component of cardiometabolic care pathways, strengthening payer negotiations for higher reimbursement tiers.
- Academia and specialist teams should incorporate adipokine panels into future RCTs that examine whether nonsurgical periodontal therapy reduces systemic inflammatory markers and antihypertensive medication burden.
Who should care
Read the original on RDH Magazine
Full reporting and any paywall content live on rdhmag.com. We summarize and score; we do not republish.
Related
- ·Business
Why the dental assistant shortage could get worse
- ·Business
US Oral Surgery Management exec on M&A: ‘We’ve had to be even more disciplined’
- ·Research
Vertical dimension of occlusion restoration using a digital injectable composite resin technique: A 5-year clinical follow-up
- ·Research
A digitally guided workflow integrating tooth preparation and restoration positioning for minimally invasive veneer and partial-coverage restorations: A dental technique